What DeciBio does

DeciBio is a precision medicine strategy consulting and market intelligence firm founded in 2009 and headquartered in Santa Monica, California. The firm delivers project-based consulting engagements spanning biomarker and diagnostics strategy, due diligence, go-to-market strategy, customer segmentation, competitive analysis, voice-of-customer research, and market landscaping and sizing. Its clients are primarily enterprise buyers across four verticals: Pharma & Biotech, Clinical Diagnostics, Research Tools, and Financial Services (including private equity and venture capital). DeciBio also publishes proprietary data products including quantitative market reports (e.g., 2026 IVD market report projecting $109B by 2030 and a 2025 proteomics tools report projecting ~$39B by 2030), DxBooks, Ad Boards, and expert transcripts, and operates a KOL/expert collaborator network with a 30% platform commission.

The firm goes to market through enterprise field sales supported by content-led demand generation: recurring newsletter franchises on AI, Digital Health and Informatics, and Liquid Biopsy, a thought-leadership blog, paid market reports, an active LinkedIn presence, and participation in industry events such as the J.P. Morgan Healthcare Conference. Pricing is project-based and quote-driven for consulting work, with data products sold as one-time licenses and an expert network monetized via marketplace commission. DeciBio has earned external recognition including Vault's Top Ranked Boutique Consulting (2023) and Great Place to Work's Best Places to Work (2025), and serves clients across the US, UK, Europe, Canada, APAC, and the Middle East.

The company's competitive advantage rests on a specialized talent bench that combines life-science depth with commercial insight, a growing proprietary content and data-asset library, and established KOL relationships that underpin primary research capabilities. As a private LLC with no disclosed funding history or institutional investors, DeciBio appears to operate as an independent, founder-led boutique that has sustained steady product, content, and geographic expansion through 2026.

Name

DeciBio

Legal name

DeciBio, LLC

Website

https://decibio.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

DeciBio is a precision medicine strategy consulting and market intelligence firm serving enterprise clients across Pharma & Biotech, Clinical Diagnostics, Research Tools, and Financial Services through project-based consulting, proprietary market reports, and a KOL expert network.

Ownership category

akta.pro rank

Headquarters

HQ city

Santa Monica

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Technology or R&D, Others

Revenue model

1. Strategy Consulting Services: DeciBio generates revenue primarily through project-based consulting engagements. Engagements include biomarker and diagnostics strategy, due diligence, go-to-market strategy, voice-of-customer research, competitive analysis, market landscaping and sizing, and customer segmentation. Projects vary in scope from targeted assessments to comprehensive market studies.
2. Data Products and Market Reports: DeciBio sells data products including market reports (IVD market reports, proteomics tools market reports, oncology genomics trackers), Ad Boards, DxBooks, and transcripts. These are published research products available for purchase through their data platforms.
3. KOL/Expert Network (Collaborator Model): DeciBio operates a collaborator/expert network where KOLs and industry experts contribute to consulting projects. The company charges collaborators a maximum commission of 30% on completed transactions for using the platform, suggesting a marketplace model for expert engagement.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

DeciBio provides project-based strategy consulting and market intelligence services to firms in clinical diagnostics, life science research tools, pharma & biotech, and financial services. Its consulting capabilities span due diligence, biomarker and diagnostics strategy, go-to-market strategy, customer segmentation, voice-of-customer research, competitive analysis, and market landscaping/sizing. The firm also sells standalone data products — Market Reports, DxBooks, Ad Boards, and Transcripts — covering precision medicine markets such as IVD and proteomics tools.

Product overview

DeciBio is a precision medicine strategy consulting firm offering a combination of consulting services and data products. The consulting services include market research (AdBoards, competitive analysis, market landscaping, KOL identification, surveys/trackers, voice-of-customer research), strategy consulting (biomarker and diagnostics strategy, customer segmentation, due diligence, go-to-market strategy, pricing strategy, revenue projection, target identification), and data analytics. The data products portfolio includes Market Reports providing quantitative market intelligence, DxBooks for diagnostic insights, Ad Boards for expert advisory services, and Transcripts of expert interviews. The company serves industries including clinical diagnostics, financial services, pharma and biotech, and research tools.

Differentiator

Problem solved

Functional benefit

Products and services

• Due Diligence Services Comprehensive due diligence capabilities covering technology, market, customers, competitors, business model, regulatory strategy, and reimbursement assessment for life sciences investments. Targeted at financial sponsors and corporate investors evaluating precision medicine targets.
• Biomarker and Diagnostics Strategy Expertise in biomarker discovery, companion diagnostic partner identification, IVD launch planning, and assay clinical journey integration for precision medicine. Targeted at pharma, biotech, and diagnostics companies developing precision medicine and CDx strategies.
• Go-to-Market Strategy Strategy consulting service focused on execution tactics, coordination, and alignment across organizations for market entry. Targeted at life sciences companies commercializing precision medicine products.
• Customer Segmentation Market research service analyzing customer needs, value propositions, decision-making drivers, and optimal customer targeting strategies for life sciences and precision medicine clients.
• Voice-of-Customer Research Primary research service conducting interviews and surveys with key stakeholders to gather market insights and customer feedback for precision medicine and life sciences clients.
• Competitive Analysis Market intelligence service profiling competitors, analyzing market positioning, and assessing competitive differentiation across precision medicine and life sciences markets.
• Market Landscaping and Sizing Quantitative market analysis including market sizing models, growth projections, and landscape assessments across precision medicine segments such as IVD, proteomics, and oncology genomics.
• Market Reports Quantitative market reports covering precision medicine segments including in vitro diagnostics, proteomics tools, and oncology genomics trackers. Available for purchase through DeciBio's data platforms as standalone one-time-license products.
• DxBooks Data product providing diagnostic and market intelligence information across precision medicine and clinical diagnostics markets.
• Ad Boards Advisory board research services connecting companies with key opinion leaders for strategic market insights on precision medicine topics.
• Transcripts Interview transcripts providing verbatim expert perspectives on precision medicine markets and technologies, available for purchase through DeciBio's data platform.

Quantifiable outcome

• DeciBio-enabled client made rapid decision to proceed with $150M growth equity investment in oncology diagnostics provider
• +1 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• ZS Associates: ZS is a large professional services firm serving pharma and biotech with strategy, sales, and marketing consulting — competes with DeciBio on commercial strategy and go-to-market engagements, though with a much broader portfolio and analytics-heavy delivery model.
• Frost & Sullivan: Frost & Sullivan is a large-scale market intelligence and consulting firm producing syndicated reports and custom consulting across life sciences, diagnostics, and healthcare — competes with DeciBio on both data products and project-based consulting, though at much broader scope.
• GlobalData: GlobalData is a large market intelligence and analytics platform covering healthcare, pharma, and medical devices with syndicated reports and consulting — directly competitive with DeciBio's market reports and due diligence data products at the high end of the market.
• Charles River Associates (Life Sciences): CRA's Life Sciences practice provides economic and strategy consulting, commercial due diligence, and litigation support to pharma, biotech, and diagnostics clients — a direct larger-scale competitor to DeciBio on enterprise consulting mandates, particularly for PE/VC commercial due diligence.
• L.E.K. Consulting: L.E.K. is a large global strategy consulting firm with a substantial Life Sciences practice covering pharma, biotech, diagnostics, and medtech — competes with DeciBio for precision medicine commercial due diligence and strategy engagements but at materially larger scale and broader portfolio.

Direct peers

• ClearView Healthcare Partners: ClearView is a life sciences strategy consulting firm serving pharma, biotech, and medical device clients with commercial due diligence, market access, and portfolio strategy — directly comparable to DeciBio's pharma/biotech commercial due diligence and biomarker strategy offerings.
• Health Advances: Health Advances is a boutique life science strategy consulting firm focused on commercial strategy, due diligence, and market assessment for pharma, biotech, diagnostics, and medtech clients — the most direct head-to-head peer to DeciBio in the precision medicine strategy space.
• Back Bay Life Science Advisors: Back Bay is a life science-focused strategy and transaction advisory firm providing commercial due diligence, capital raising, and licensing support to pharma, biotech, and medtech clients — overlapping directly with DeciBio's financial services and pharma/biotech due diligence mandates.

Emerging players

• Definitive Healthcare: Definitive Healthcare provides a healthcare commercial intelligence platform with data on providers, diagnostics, and life sciences — an emerging data-product peer to DeciBio's DxBooks and market reports, though anchored in provider data rather than market/sizing data.
• Roots Analysis: Roots Analysis is a market research firm publishing syndicated reports on life science and healthcare markets, including diagnostics, omics, and precision medicine — closely comparable to DeciBio's IVD, proteomics, and oncology genomics market reports business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DeciBio